Authors


Katherine B. Peters, MD, PhD

Latest:

Dr Peters on Vorasidenib in Residual or Recurrent IDH1/2-Mutant Glioma

Katherine B. Peters, MD, PhD, discusses findings from the phase 3 INDIGO trial of vorasidenib in patients with recurrent or residual grade 2 glioma harboring an IDH1 or IDH2 mutation and how these results support the addition of vorasidenib to the treatment armamentarium. 


Susan D. Klugman, MD, FACOG, FACMG

Latest:

The Role of Genetics in Cancer Care Continues to Expand

Genetic screening and testing have only recently become an integral part of cancer care.


Benjamin Diamond, MD

Latest:

Dr. Diamond on the Need to Integrate MRD Testing Into Clinical Trials in Multiple Myeloma

Benjamin Diamond, MD, discusses the need to integrate minimal residual disease testing into clinical trials in multiple myeloma.


Aung Naing, MD, FACP

Latest:

Dr. Naing on the Potential Implications of Immune-Related Adverse Effects in Cancer

Aung Naing, MD, FACP, discusses potential immune-related adverse effects in oncology.


Meredith McKean, MD, MPH

Latest:

The Future of Metastatic and Unresectable Melanoma Treatment

The panel concludes their discussion with a call for continued research and collaboration, emphasizing the need for more understanding of targeted therapies, monitoring tools like ctDNA, and ongoing development in the field of BRAF mutant melanoma treatment.


Sandra L. Starnes, MD

Latest:

Women in Oncology: Self-Advocacy in a Busy Field

Melinda Butsch Kovacic, MPH, PhD; Elizabeth Shaughnessy, MD, PhD; Sandra L. Starnes, MD; and Susan E. Waltz, PhD, discuss the advice they would give to their younger selves and future female oncology professionals, knowing what they know now about the oncology field and their own career growth.


Arash Rezazadeh Kalebasty, MD

Latest:

CAR T-Cell Therapy in Metastatic CRPC and Future Directions in Care

Closing out their final module, expert panelists consider the role of CAR T-cell therapy in metastatic castration-resistant prostate cancer and look toward future evolutions in the broader treatment landscape.


Neelima Vidula, MD

Latest:

Dr Vidula on the Evaluation of Talazoparib in BRCA1/2-Mutated Metastatic Breast Cancer

Neelima Vidula, MD, discusses an ongoing phase 2 study evaluating the highly potent PARP inhibitor talazoparib in patients with somatic BRCA1/2-mutated metastatic breast cancer.


Cindy Varga, MD

Latest:

Dr. Varga on Current Clinical Trials for Patients with Relapsed/Refractory Multiple Myeloma

Cindy Varga, MD, discusses several exciting clinical trials at the Levine Cancer Institute for patients with relapsed/refractory multiple myeloma with acquired resistance to BCMA-directed therapy.


Johannes Schetelig, MD, MSc

Latest:

Dr. Schetelig on the Use of Induction Chemotherapy Prior to Allo-HCT in Relapsed/Refractory AML

Johannes Schetelig, MD, MSc, discusses whether patients with active relapsed/refractory acute myeloid leukemia (AML) should receive remission induction chemotherapy prior to undergoing allogenic hematopoietic stem cell transplant (allo-HCT).


Matthew Tucker, MD

Latest:

The Power of No, the Value of Yes

Brian I. Rini, MD, and Matthew Tucker, MD, sit down to discuss developing a career path and building a résumé, the value of writing review articles early in fellowship, the power of saying no, and the importance of saying yes.


Dipti Patel-Donnelly, MD

Latest:

Dr Patel-Donnelly on the Management of High-Risk Hematologic Malignancies in the Community

Dipti Patel-Donnelly, MD, discusses the management of high-risk hematologic malignancies in community practice.


Sam Brondfield, MD, MAEd

Latest:

Building Upon Scaffolds

Cancer care is changing rapidly, and understanding and incorporating new practices is challenging both for practicing oncologists and oncology trainees.


Echo L. Warner, PhD, MPH

Latest:

Fellows Can Join the Fight Against Cancer Misinformation Online

Many cancer organizations across the United States and internationally acknowledge a need for in-novative uses of social technology to improve cancer-related support and information provision.


Chasity M. Washington, MPH, CHES

Latest:

Washington on Efforts to Address Disparities in Cancer Care

Chasity Washington, MPH, CHES, discusses strategies for addressing disparities in cancer care.


Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO

Latest:

Dr. Mogal on the Role of Cytoreductive Surgery in Colorectal Peritoneal Carcinomatosis

Harveshp D. Mogal, MD, MS, FACS, DABS, FSSO, discusses the role of cytoreductive surgery in colorectal peritoneal carcinomatosis.


Kimberly A. Spickes, CNP

Latest:

Advice for New Nurse Practitioners Working With Patients With Endometrial Cancer

Closing their discussion, the panel shares advice for new nurse practitioners caring for patients who have endometrial cancer.


Omar Alkharabsheh, MD

Latest:

Dr. Alkharabsheh on Remaining Challenges in High-Risk CLL

Omar Alkharabsheh, MD, discusses remaining challenges in high-risk chronic lymphocytic leukemia.


Linda Perry, PA-C

Latest:

Using Multidisciplinary Care to Optimize Outcomes in GVHD

Sharing closing thoughts on acute and chronic GVHD management, expert panelists first consider the value of multidisciplinary care.


Christopher Flowers, MD

Latest:

Zanubrutinib plus Obinutuzumab versus Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma: Updated Analysis of the ROSEWOOD Study

Dr. Christopher Flowers showcases a comprehensive and updated analysis of the ROSEWOOD study, evaluating the efficacy and safety of combining zanubrutinib with obinutuzumab versus obinutuzumab monotherapy.


Sarah Donahue, MPH, NP, AOCNP

Latest:

Practice Pearls for Toxicity Management With ADC Therapy in Breast and Gastric Cancer

Shared practical advice on the management of toxicities associated with antibody drug conjugate therapy in both the breast cancer and GI cancer settings.


Aurelie Garant, MD, UT Southwestern Medical Center

Latest:

Multidisciplinary Strategies in RCC Management: Future Directions in Care

Closing out their discussion on renal cell carcinoma, key opinion leaders highlight the value of multidisciplinary care and look toward future evolutions in the treatment paradigm.


Craig Cole, MD

Latest:

Putting Culturally Competent Care into Practice

Joseph Mikhael, MD, and Craig Cole, MD, close the program by sharing examples of times culturally competent care was paramount to the treatment of their patients.


Ilana Schlam, MD

Latest:

Trainees Deserve Better Feedback

Feedback plays a key role in medical edu-cation and faculty development as it allows everyone to evaluate their performance and improve their intrapersonal skills.



Sandra Toogood

Latest:

Novel Frontline Combinations Influence Later-Line Treatment Strategies in SCLC

While progress in outcomes has been greater in non–small cell lung cancer, recent advances, including molecularly targeted therapies against EGFR and ALK, checkpoint inhibitors that boost immune response, improved staging, and video-assisted surgery have all contributed to progress in treatment of all types of lung cancer, including in SCLC.


Valeria Santini, MD

Latest:

Unmet Needs and Future of Lower-Risk MDS

The panel concludes their discussion with a look toward the future of lower-risk myelodysplastic syndrome treatment and the unmet needs that should be addressed.


Nicholas Wrigley

Latest:

Polatuzumab Vedotin Substitution in R-mini-CHOP Does Not Worsen High-Grade Toxicities in DLBCL

Using polatuzumab vedotin instead of vincristine in a reduced-dose regimen of rituximab, cyclophosphamide, doxorubicin, and prednisone was not found to increase grade 3/4 hematologic toxicities, infection risk, or neuropathy in elderly patients with untreated diffuse large B-cell lymphoma.


Lubna N. Chaudhary, MD

Latest:

Dr Chaudhary on the Utilization of Trastuzumab Deruxtecan in Metastatic HER2+ Breast Cancer

Lubna Chaudhary, MD, MS, discusses the ongoing investigation and utilization of trastuzumab deruxtecan in patients with metastatic HER2-positive breast cancer and compared this agent’s efficacy with that of trastuzumab emtansine.


Stephen V. Liu, MD, Georgetown University

Latest:

Dr Liu on the Activity of Trastuzumab Deruxtecan in HER2-Mutated NSCLC

Stephen V. Liu, MD, discusses the activity of trastuzumab deruxtecan in patients with HER2-mutated non–small cell lung cancer.